Modulation of cell division by an early mitotic inhibitor protein
CA 2448360 A1 · Owner: The Board Of Trustees Of The Leland Stanford Junior University · Inventors: Jackson, Peter K.; Reimann, Julie D. R.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Emi1 regulates progression through early mitosis by preventing premature APC activation. Depleting Emi1 from cycling cells strongly delays cyclin B accumulation and mitotic entry, while expression of a stabilized form of Emi1 stabilizes APC substrates and causes a mitotic block. Emi1 binds the APC activators Cdc20 and Cdh1 and inhibits APC activation by Cdc20 or Cdh1. Hence products that modulate the expression and/or activity of Emi1 have a therapeutic effect in the treatment of cancer leukemia, solid tumors, chronic , or acute inflammatory disease restenosis, diabetes, neurological disorders arthritis and osteoporosis, among other indications.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 23, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 23, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 23, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.